Truist Financial Corp Exagen Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$4.18 - $7.74 $923 - $1,710	-221 Reduced 1.85%	11,740 $67,000
Q1 2022 Apr 22, 2022	SELL	$7.12 - $11.06 $2,057 - $3,196	-289 Reduced 2.36%	11,961 $96,000
Q4 2021 Feb 14, 2022	SELL	$8.97 - $14.08 $14,683 - $23,048	-1,637 Reduced 11.79%	12,250 $142,000
Q3 2021 Nov 05, 2021	SELL	$10.25 - $15.21 $5,637 - $8,365	-550 Reduced 3.81%	13,887 $189,000
Q2 2021 Aug 16, 2021	SELL	$12.4 - $17.92 $12,238 - $17,687	-987 Reduced 6.4%	14,437 $216,000
Q1 2021 May 17, 2021	BUY	$13.9 - $22.0 $214,393 - $339,328	15,424 New	15,424 $270,000

6.29M

2.5K

200

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $50.2M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.